Dr. Alan Spatz is professor in the departments of Pathology and Oncology at McGill University, director of the division of Pathology of the McGill University Health Center that is an integrated network of 12 pathology labs, site-chief of Molecular genetics at the Jewish General Hospital of Montreal, and director of the research Molecular Pathology Center at the Lady Davis Institute and Segal Cancer Centre. He serves on the board of many international and Canadian research organizations and on the editorial boards of several prestigious journals. He has recently been appointed as a member of the Correlative Sciences Committee of the US National Cancer Institute.
Dr. Spatz worked from 1994 to 2008 at Gustave Roussy cancer institute in Villejuif, France, and was a board member of the European Organization for Research and Treatment of Cancer (EORTC), Chair of the EORTC Melanoma and Pathobiology groups, President of the French division of the International Academy of Pathology, and Chair of the Melanoma committee of the Canadian Cancer Trials Group (CCTG). He is active on the Board of Directors of the WIN international consortium (winconsortium.org), and of the EXACTIS-Innovation pan-Canadian network for precision medicine (exactis.ca).
His research lab is focused on the specific mechanisms of X chromosome inactivation and its connection with cancer. His lab has deciphered the role of the PPP2R3B protein in melanoma progression and its main partners and has demonstrated the functional role in cancer of sex-related haploinsufficiency. His research, mainly focused on melanoma and lung cancer biomarkers, is also oriented towards the role of the interaction between CTCF and BORIS using X chromosome inactivation as a model of chromatin remodeling. He has authored more than 210 original scientific papers and books including as a senior author in Lancet, Lancet Oncology, Science Translational Medicine, Nature Reviews Cancer, and Journal of Clinical Oncology.